128 related articles for article (PubMed ID: 35896222)
1. Significance of the Multi-gene Panel myRisk in Japan.
Hayashi S; Kubo M; Matsuzaki S; Kai M; Morisaki T; Yamada M; Kaneshiro K; Takao Y; Shimazaki A; Nagayoshi K; Mizuuchi Y; Nakamura M
Anticancer Res; 2022 Aug; 42(8):4097-4102. PubMed ID: 35896222
[TBL] [Abstract][Full Text] [Related]
2. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.
LaDuca H; Polley EC; Yussuf A; Hoang L; Gutierrez S; Hart SN; Yadav S; Hu C; Na J; Goldgar DE; Fulk K; Smith LP; Horton C; Profato J; Pesaran T; Gau CL; Pronold M; Davis BT; Chao EC; Couch FJ; Dolinsky JS
Genet Med; 2020 Feb; 22(2):407-415. PubMed ID: 31406321
[TBL] [Abstract][Full Text] [Related]
3. Should all patients undergoing genetic testing for hereditary breast cancer syndromes be offered a multigene panel?
Silver EL; Niell-Swiller M
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):36-40. PubMed ID: 34967813
[TBL] [Abstract][Full Text] [Related]
4. Utility of germline multi-gene panel testing in patients with endometrial cancer.
Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
[TBL] [Abstract][Full Text] [Related]
5. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract][Full Text] [Related]
6. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
7. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
8. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
[TBL] [Abstract][Full Text] [Related]
9. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
[TBL] [Abstract][Full Text] [Related]
10. Detection of BRCA1 Pathogenic Variant in a 24-Year-Old Endometrial Cancer Patient: Risks of Several Hereditary Tumor Syndromes Assessed Using Germline Multigene Panel Testing.
Wang X; Kaneko K; Arakawa H; Habano E; Omi M; Nakashima E; Kawachi H; Tonooka A; Omatsu K; Nomura H; Yunokawa M; Kanao H; Takahashi S; Nakajima T; Ueki A
Case Rep Oncol; 2022; 15(2):792-797. PubMed ID: 36157696
[TBL] [Abstract][Full Text] [Related]
11. Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study.
Levine MD; Pearlman R; Hampel H; Cosgrove C; Cohn D; Chassen A; Suarez A; Barrington DA; McElroy JP; Waggoner S; Nakayama J; Billingsley C; Resnick K; Andrews S; Singh S; Jenison E; Clements A; Neff R; Goodfellow PJ;
JCO Precis Oncol; 2021 Nov; 5():1588-1602. PubMed ID: 34994648
[TBL] [Abstract][Full Text] [Related]
12. Germline whole genome sequencing in adults with multiple primary tumors.
Wang Y; Ding Q; Prokopec S; Farncombe KM; Bruce J; Casalino S; McCuaig J; Szybowska M; van Engelen K; Lerner-Ellis J; Pugh TJ; Kim RH
Fam Cancer; 2023 Oct; 22(4):513-520. PubMed ID: 37481477
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience.
Calvello M; Marabelli M; Gandini S; Marino E; Bernard L; Dal Molin M; Di Cola G; Zanzottera C; Corso G; Fazio N; Gervaso L; Fumagalli Romario U; Barberis M; Guerrieri-Gonzaga A; Bertario L; Serrano D; Bonanni B
Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239438
[TBL] [Abstract][Full Text] [Related]
14. Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield.
Horton C; LaDuca H; Deckman A; Durda K; Jackson M; Richardson ME; Tian Y; Yussuf A; Jasperson K; Else T
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1917-e1923. PubMed ID: 35026032
[TBL] [Abstract][Full Text] [Related]
15. Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test.
Shin HC; Lee HB; Yoo TK; Lee ES; Kim RN; Park B; Yoon KA; Park C; Lee ES; Moon HG; Noh DY; Kong SY; Han W
Cancer Res Treat; 2020 Jul; 52(3):697-713. PubMed ID: 32019277
[TBL] [Abstract][Full Text] [Related]
16. Characterization of POT1 tumor predisposition syndrome: Tumor prevalence in a clinically diverse hereditary cancer cohort.
Herrera-Mullar J; Fulk K; Brannan T; Yussuf A; Polfus L; Richardson ME; Horton C
Genet Med; 2023 Nov; 25(11):100937. PubMed ID: 37466057
[TBL] [Abstract][Full Text] [Related]
17. Mutation prevalence tables for hereditary cancer derived from multigene panel testing.
Hart SN; Polley EC; Yussuf A; Yadav S; Goldgar DE; Hu C; LaDuca H; Smith LP; Fujimoto J; Li S; Couch FJ; Dolinsky JS
Hum Mutat; 2020 Aug; 41(8):e1-e6. PubMed ID: 32442341
[TBL] [Abstract][Full Text] [Related]
18. Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases.
Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
[TBL] [Abstract][Full Text] [Related]
19. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
[TBL] [Abstract][Full Text] [Related]
20. Quality of Clinician-Reported Cancer History When Ordering Genetic Testing.
LaDuca H; McFarland R; Gutierrez S; Yussuf A; Ho N; Pepper J; Reineke P; Cain T; Blanco K; Horton C; Dolinsky JS
JCO Clin Cancer Inform; 2018 Dec; 2():1-11. PubMed ID: 30652589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
